Vimarsana
Biggest News Aggregation in the World

Irit Aish News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Irit Aish. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Irit Aish Today - Breaking & Trending Today

Pharma Two B Announces Positive Topline Results from its Pivotal Phase III Study of P2B001 in Early Parkinson's Disease - Vimarsana News

Pharma Two B Announces Positive Topline Results from its Pivotal Phase III Study of P2B001 in Early Parkinson's Disease

/PRNewswire/ -- Pharma Two B Ltd., a privately held company developing innovative therapeutics based on reformulation and combinations of previously approved...

Pharma Two B Announces Positive Topline Results from its Pivotal Phase III Study of P2B001 in Early Parkinson's Disease - Vimarsana News

Pharma Two B Announces Positive Topline Results from its Pivotal Phase III Study of P2B001 in Early Parkinson's Disease

/PRNewswire/ -- Pharma Two B Ltd., a privately held company developing innovative therapeutics based on reformulation and combinations of previously approved...

Pharma Two B Announces Positive Topline Results from its Pivotal Phase III Study of P2B001 in Early Parkinson's Disease - Vimarsana News

Pharma Two B Announces Positive Topline Results from its Pivotal Phase III Study of P2B001 in Early Parkinson's Disease

/PRNewswire/ -- Pharma Two B Ltd., a privately held company developing innovative therapeutics based on reformulation and combinations of previously approved...

Pharma Two B Ltd.: Pharma Two B Announces Positive Topline Results from its Pivotal Phase III Study of P2B001 in Early Parkinson's Disease - Vimarsana News

Pharma Two B Ltd.: Pharma Two B Announces Positive Topline Results from its Pivotal Phase III Study of P2B001 in Early Parkinson's Disease

Study successfully met its primary and key secondary endpoints, demonstrating superior efficacy of P2B001 compared to its individual components P2B001 showed comparable efficacy to a marketed